Clinical Trials Logo

Carcinoma Breast clinical trials

View clinical trials related to Carcinoma Breast.

Filter by:

NCT ID: NCT05603013 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Start date: October 30, 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory non-small cell lung cancer and breast cancer.

NCT ID: NCT05507034 Recruiting - Chronic Pain Clinical Trials

Identifying Biomarkers for Chronic Pain After Breast Cancer Treatment.

sCANsens
Start date: October 4, 2022
Phase:
Study type: Observational

Up to 40% of women experience chronic pain after treatment for breast cancer, and this pain is often very disabling. However, chronic pain after breast cancer remains under-recognised and undertreated. An effective and patient-tailored approach of (chronic) pain after breast cancer indeed requires a thorough knowledge and evaluation of the pain. In daily clinical practice, however, guidelines for a comprehensive diagnosis of pain in cancer patients and survivors are lacking. Further research in this topic is crucial for an efficient, preventive as well as curative, approach of pain after breast cancer. Besides the high prevalence and the important impact of pain in this population, the breast cancer population is also an ideal population to study chronic pain and its natural time course in different stages, since most patients start pain-free, but almost half of them end up with chronic pain. Therefore, this study aims to map biomarkers (both predictive, prognostic and diagnostic) for chronic pain after breast cancer treatment. We will study possible biopsychosocial biomarkers in relation to (chronic) pain and monitor their temporal changes from the moment of diagnosis until 1 year after surgery. The potential biomarkers are situated within the medical imaging of the brain, measurements of pain sensitivity and psychological variables.

NCT ID: NCT05461430 Recruiting - Pancreatic Cancer Clinical Trials

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

TraveraRTGx
Start date: July 15, 2022
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

NCT ID: NCT04985357 Not yet recruiting - Clinical trials for Carcinoma, Non-Small-Cell Lung

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

Start date: June 2024
Phase:
Study type: Observational

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

NCT ID: NCT04790305 Recruiting - Clinical trials for Triple-negative Breast Cancer

Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer

Start date: June 18, 2021
Phase: Phase 4
Study type: Interventional

This is a prospective, multicenter, randomized, parallel controlled, open-label study. The primary purpose of this study is to evaluate the efficacy of Huaier Granule on postoperative adjuvant therapy of high-risk early-stage triple-negative invasive ductal carcinoma. The Secondary purposes are to evaluate the safety of long-term use of Huaier granules as postoperative adjuvant treatment of high-risk early-stage triple-negative invasive ductal carcinoma, and the changes of quality of life score after treatment with Huaier granule.

NCT ID: NCT03768492 Active, not recruiting - Carcinoma Breast Clinical Trials

Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy

ReDCoAT
Start date: December 13, 2019
Phase: Phase 2
Study type: Interventional

The purpose of the study is to evaluate whether a caffeine-based cream can reduce the rates of reconstructive complications in patients with tissue expander based reconstruction requiring post-mastectomy radiation therapy when compared to a placebo cream.

NCT ID: NCT03113825 Completed - Clinical trials for Breast Cancer Female

Study of AVB-620 in Women With Primary, Nonrecurrent Breast Cancer Undergoing Surgery

Start date: July 5, 2017
Phase: Phase 2
Study type: Interventional

Phase 2, open-label study of AVB-620 in women with primary, nonrecurrent and nonmetastatic breast cancer undergoing surgery.

NCT ID: NCT03002766 Completed - Carcinoma Breast Clinical Trials

Ten Years Results of a Score System to Address Adjuvant Therapies After Breast Conserving Surgery for Ductal Carcinoma in Situ of the Breast

DCIS
Start date: March 2000
Phase: Phase 2
Study type: Interventional

By this non-randomized prospective study, it's evaluated the outcome of patients underwent BCS for DCIS at whom an established score system to address adjuvant therapies have been prospectively applied, according to the wideness of free margins. Between March 2000 and April 2006, 224 patients were enrolled and followed within the study.

NCT ID: NCT01849133 Completed - Carcinoma Breast Clinical Trials

Randomized Trial on Intraoperative Radiotherapy Full Dose Vs External Radiotherapy

ELIOT
Start date: November 2000
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate the efficacy of exclusive intraoperative radiation therapy after conserving surgery in early-stage breast cancer compared with whole breast radiotherapy. The primary outcome was the rate of ipsilateral true recurrence ( any recurrence at or close to primary tumor bed) and new ipsilateral tumors ( any recurrence occurring in quadrants other than the previous one) and the recurrence free survival.

NCT ID: NCT00043394 Completed - Carcinoma, Breast Clinical Trials

CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer

Start date: September 2002
Phase: Phase 2
Study type: Interventional

To determine the safety and efficacy of CPG 7909 Injection given with Herceptin to patients with metastatic breast cancer.